Tivic Health shares jump 12.44% intraday after securing BARDA meeting for Entolimod development.

Tivic Health Systems (TIVC) surged 12.44% intraday following the announcement on November 18, 2025, that it secured a meeting with BARDA to discuss Entolimod's development for acute radiation syndrome. The news highlighted Entolimod's FDA Fast Track and Orphan Drug designations, potential government partnership opportunities, and its therapeutic promise in radiation injury. The meeting is expected to clarify development pathways, fueling investor optimism about commercialization prospects. The second news item, referencing Yahoo Finance's cumulative return data dated November 14, lacked specific events to explain the intraday rally. Thus, the stock's sharp rise aligns with the BARDA-related milestone, underscoring strategic progress for the company's lead candidate.